Eurofins Genomics provides analytical solutions under the ISO17025 quality standard for applications in veterinary medicine, pharmaceutical testing, food, feed and commodity testing as well as in health care. The latter includes medical laboratory testing in the context of clinical studies and genetic diagnostics.
Eurofins Genomics ISO17025 accreditation covers mass spectrometry based DNA analysis and molecular testing methods, for example Sanger sequencing, quantitative Real-Time PCR and fragment length polymorphisms analysis.
In April 2014, next generation sequencing (NGS) technologies based on Illumina and Roche 454 platforms were added to extend the Eurofins Genomics ISO17025 accredited service portfolio. "The addition of our next generation sequencing services to our ISO17025 accreditation was the next logical step in response to our growing customer base in the regulated market and in areas with specific quality assurance needs." says Peter Persigehl, General Manager Eurofins Genomics Europe.
"With the extension of our ISO17025 accredited service portfolio to NGS, Eurofins Genomics is even more capable to provide of providing tailored solutions for customers rapidly growing and new fields of applications" says Bruno Poddevin, Senior Vice-President Eurofins Genomics.
Illumina is a trademark of Illumina / 454 is a trademark of Roche.
Weiterführende Informationen finden sich hier:
http://www.eurofinsgenomics.eu/...
http://www.eurofinsgenomics.eu/...